Immunologically defined subclasses of the protein kinase CK2 β-subunit in prostate carcinoma cell lines

Götz, Claudia; Kartarius, Sabine; Schetting, Sarah; Montenarh, Mathias

doi:10.1007/s11010-005-2950-2

Cited by 8 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among solid tumors, overexpression and/or important roles have been found for CK2 in glioblastoma, 94 – 98 medulloblastoma, 99 , 100 prostate cancers, 101 – 103 ovarian cancers, 104 – 107 breast cancers, 72 , 108 – 112 head and neck squamous cell cancers, 62 , 113 , 114 lung cancers, 113 , 115 – 117 melanoma, 118 , 119 renal cell carcinoma, 73 , 120 – 122 bladder cancers, 123 , 124 pancreatic cancers, 125 , 126 cholangiocarcinoma, 36 , 127 esophageal cancers, 128 , 129 gastric cancers, 130 – 133 hepatocellular carcinoma, 134 – 137 mesothelioma, 138 cervical cancers, 139 – 141 and other squamous cell carcinoma. 142 In this list, the references quote the first chronological evidence and the most relevant findings of CK2 overexpression or fundamental roles in the indicated type of tumor (not considering the many publications dealing with CK2 inhibitor treatment, unless conclusions highlighted specific CK2 functions in the treated tumor).…”

Section: Ck2 In Human Diseasesmentioning

confidence: 99%

Protein kinase CK2: a potential therapeutic target for diverse human diseases

Borgo

D’Amore

Sarno

et al. 2021

Sig Transduct Target Ther

218

180

View full text Add to dashboard Cite

CK2 is a constitutively active Ser/Thr protein kinase, which phosphorylates hundreds of substrates, controls several signaling pathways, and is implicated in a plethora of human diseases. Its best documented role is in cancer, where it regulates practically all malignant hallmarks. Other well-known functions of CK2 are in human infections; in particular, several viruses exploit host cell CK2 for their life cycle. Very recently, also SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been found to enhance CK2 activity and to induce the phosphorylation of several CK2 substrates (either viral and host proteins). CK2 is also considered an emerging target for neurological diseases, inflammation and autoimmune disorders, diverse ophthalmic pathologies, diabetes, and obesity. In addition, CK2 activity has been associated with cardiovascular diseases, as cardiac ischemia–reperfusion injury, atherosclerosis, and cardiac hypertrophy. The hypothesis of considering CK2 inhibition for cystic fibrosis therapies has been also entertained for many years. Moreover, psychiatric disorders and syndromes due to CK2 mutations have been recently identified. On these bases, CK2 is emerging as an increasingly attractive target in various fields of human medicine, with the advantage that several very specific and effective inhibitors are already available. Here, we review the literature on CK2 implication in different human pathologies and evaluate its potential as a pharmacological target in the light of the most recent findings.

show abstract

Section: Ck2 In Human Diseasesmentioning

confidence: 99%

Protein kinase CK2: a potential therapeutic target for diverse human diseases

Borgo

D’Amore

Sarno

et al. 2021

Sig Transduct Target Ther

218

180

View full text Add to dashboard Cite

show abstract

“…Phosphorylation of β-Ser209 by Cdk1/ cyclin B enhances CK2 activity in prostate cancer cells. 32 This can be explained by the weakening of the interaction in trimers between β-Ser209 and α-Glu230, residues at only 3.0 Å in α2β2 new . Moreover, phosphorylation of β-Thr213 by Chk1 affects the free β-subunit but not the holoenzyme 33 where, in the trimeric organization, this residue is not accessible.…”

mentioning

confidence: 99%

Structural Determinants of Protein Kinase CK2 Regulation by Autoinhibitory Polymerization

2012

View full text Add to dashboard Cite

CK2 is a Ser/Thr protein kinase essential for cell viability whose activity is anomalously high in several cancers. CK2 is a validated target for cancer therapy with one small molecule inhibitor in phase I clinical trials. This enzyme is not regulated by mechanisms common to other protein kinases, and how its activity is controlled is still unclear. We present a new crystal structure of the CK2 holoenzyme that supports an autoinhibitory mechanism of regulation whereby the β-subunit plays an essential role in the formation of inactive polymeric assemblies. The derived structural model of (down)regulation by aggregation contributes to the interpretation of biochemical and functional data and paves the way for new strategies in the modulation of CK2 activity and for the design of non-ATP-competitive inhibitors targeting the interaction between the α catalytic and the β regulatory subunits.

show abstract

“…A cell extract of SH-SY5Y cells was incubated either with serum #26 (specific of CK2a), serum #30 (specific for CK2a) [17] or serum #269 (specific for CK2b) [18]. The immunoprecipitates were analyzed on an SDS-10 % polyacrylamide gel.…”

Section: Resultsmentioning

confidence: 99%

“…Antibodies and Western blot analysis. To detect CK2 we used rabbit anti-peptide sera #26 (a-subunit), #30 (a-subunit) and #269 (b-subunit) [17,18] and the monoclonal antibodies 1A5 [19] (a-subunit), 1AD9 (a and a subunit) [20] and 6D5 (b-subunit) [21]. Rabbit serum #976 was raised against a peptide corresponding to amino acids 393-405 (CDNTPIIDNIAPV) of the KIF5C protein.…”

Section: Methodsmentioning

confidence: 99%

KIF5C: A new binding partner for protein kinase CK2 with a preference for the CK2α’ subunit

Schäfer

Götz

Dudek

et al. 2008

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Protein kinase CK2 is a highly conserved serine/threonine kinase that is ubiquitously expressed in eukaryotic cells. CK2 is a constitutively active tetrameric enzyme composed of two catalytic alpha and/or alpha'-subunits and two regulatory beta-subunits. There is increasing evidence that the individual subunits may have independent functions and that they are asymmetrically distributed inside the cell. To gain a better understanding of the functions of the individual subunits, we employed a yeast-two-hybrid screen with CK2alpha and CK2alpha'. We identified the motor neuron protein KIF5C as a new binding partner for CK2. The interaction found in the yeast-two-hybrid screen was confirmed by co-sedimentation analysis on a sucrose density gradient and by co-immunoprecipitation analysis. Pull-down experiments and surface plasmon resonance spectrometry revealed a direct binding of KIF5C to CK2alpha'. Co-localization studies with neuroblastoma cells, bone marrow and with primary neurons confirmed the biochemical analysis that KIF5C preferentially bound to CK2alpha'.

show abstract

Immunologically defined subclasses of the protein kinase CK2 β-subunit in prostate carcinoma cell lines

Cited by 8 publications

References 37 publications

Protein kinase CK2: a potential therapeutic target for diverse human diseases

Protein kinase CK2: a potential therapeutic target for diverse human diseases

Structural Determinants of Protein Kinase CK2 Regulation by Autoinhibitory Polymerization

KIF5C: A new binding partner for protein kinase CK2 with a preference for the CK2α’ subunit

Contact Info

Product

Resources

About